The Tumor Marker: Vascular Endothelial Growth Factor 165 (VEGF165)

Tumor, as an abnormal mass of cells, has blood vessels of various sizes that can be seen everywhere on the surface and deep within it. Nutrients for life are continuously supplied to the depths of tumor cells through these blood vessels. As the tumor continues to grow, nearby blood vessels also undergo rapid and chaotic growth, with these newly formed capillaries appearing disorganized, much like the tumor itself.

Vascular Endothelial Growth Factor (VEGF) is a highly biologically active functional glycoprotein. It is a specific and potent mitogen for endothelial cells, playing a role in their proliferation, migration, and lumen formation. VEGF is involved in angiogenesis and increases capillary permeability. It can induce abnormal growth of tumor blood vessels, hinder the effective delivery of anti-tumor drugs to tumor tissues, and stimulate the production of new blood vessel growth factors.

Most tumor patients are diagnosed in the middle to late stages, and early screening and timely diagnosis of suspicious or asymptomatic patients can improve the survival rate of tumor patients and prolong their overall survival. Early detection and treatment are of significant importance in tumor screening. VEGF is produced in large quantities during the transition of tumor cell clusters into solid tumors, which often occurs in the Tis and T1 stages of the tumor. This period represents the optimal time for tumor screening and can be diagnosed through existing clinical methods. On the other hand, other tumor markers are predominantly produced in stage III and IV tumors, and they have little significance in early screening.

Tumor molecular diagnostic reagents are primarily used for detecting gene mutation sites, which can be measured when there is a variation in tumor cells. However, some dormant tumor cells may exist in the normal population, and some dormant periods can last up to 10 years. During this period, detecting these cells does not provide a definitive diagnosis but can only serve as a risk assessment for tumors. It does not have screening significance and can cause great anxiety to the screening subjects. VEGF is considered the most meaningful marker for blood tumor screening.

• Early Detection: It enables early detection of tumors during their development, allowing for early treatment.
• Broad Spectrum: It can cover almost all types of tumors, significantly reducing the risk of missed diagnosis.
• High Sensitivity: It has a high sensitivity of up to 79.4% and a high specificity of up to 97.3%.
• Dynamic: It allows for the observation of disease changes and progression by monitoring variations in VEGF levels at different stages.

VEGF has five different subtypes, named based on the number of amino acids: VEGF121、VEGF145, VEGF165, VEGF189, VEGF206, with the pervasive form of VEGF165. 

Recombinant Human VEGF165

Recombinant Rat VEGF 164

Recombinant Mouse VEGF 164

Recombinant Human VEGF 121

Recombinant Human VEGF 121 (C-6His)